Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
Sign Up to like & getrecommendations! Published in 2020 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.0c00474
Abstract: Deferoxamine mesylate (DFO) is an FDA-approved, hexadentate iron chelator routinely used to alleviate systemic iron burden in thalassemia major and sickle cell patients. Iron accumulation in these disease states results from the repeated blood transfusions… read more here.
Keywords: dfo treatment; alzheimer disease; treatment; disease ... See more keywords